AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21741829 — intervention group
Group type: COMPARATOR
Intervention: No anti-HER2 treatment after 2nd progression
Number of subjects: 151
Study 19629145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 30
Study 19629145 — intervention group
Group type: COMPARATOR
Intervention: Portland Cement (PC)
Number of subjects: 30
Study 16500339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) with 90 mL of oral sodium phosphate (NaP)
Number of subjects: 162
Study 16500339 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 162
Study 12831259 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulators of malingering
Number of subjects: 0
Study 12831259 — intervention group
Group type: COMPARATOR
Intervention: Controls (not feigning)
Number of subjects: 0
Study 12580206 — intervention group
Group type: EXPERIMENTAL
Intervention: Object display
Number of subjects: 0
Study 12580206 — intervention group
Group type: COMPARATOR
Intervention: Object Minus Shapes display
Number of subjects: 0
Study 12580206 — intervention group
Group type: COMPARATOR
Intervention: SSSI Numeric display
Number of subjects: 0
Study 8880181 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended EOAEs generated by 1 or 2 kHz tone pips
Number of subjects: 70
Study 8880181 — intervention group
Group type: COMPARATOR
Intervention: Unattended EOAEs generated by 1 or 2 kHz tone pips
Number of subjects: 70
Study 1519210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivy method
Number of subjects: 134
Study 1519210 — intervention group
Group type: COMPARATOR
Intervention: Simplate II method (horizontal direction)
Number of subjects: 134
Study 1519210 — intervention group
Group type: COMPARATOR
Intervention: Simplate II method (vertical direction)
Number of subjects: 134
Study 6087702 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition for 4 weeks
Number of subjects: 31
Study 6087702 — intervention group
Group type: COMPARATOR
Intervention: Self-regulated oral diet (control group)
Number of subjects: 31
Study 6087702 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 31
Study 30995693 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face counselling (usual care)
Number of subjects: 141
Study 30995693 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninteractive instructional video
Number of subjects: 141
Study 30995693 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video
Number of subjects: 141
Study 31113448 — intervention group
Group type: EXPERIMENTAL
Intervention: 'high in' warning FOP label
Number of subjects: 3584
Study 31113448 — intervention group
Group type: COMPARATOR
Intervention: All tax conditions
Number of subjects: 3584
Study 31113448 — intervention group
Group type: COMPARATOR
Intervention: 'sugary drink' taxes
Number of subjects: 3584
Study 28581356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab added to standard adjuvant chemotherapy plus 1 year of trastuzumab
Number of subjects: 4805
Study 28581356 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to standard adjuvant chemotherapy plus 1 year of trastuzumab
Number of subjects: 4805
Study 28581356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab in node-positive cohort
Number of subjects: 4805
Study 28581356 — intervention group
Group type: COMPARATOR
Intervention: Placebo in node-positive cohort
Number of subjects: 4805
Study 28581356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab in node-negative cohort
Number of subjects: 4805
Study 28581356 — intervention group
Group type: COMPARATOR
Intervention: Placebo in node-negative cohort
Number of subjects: 4805
Study 28581356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 4805
Study 28581356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4805
Study 26406018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo Ni‐Ti rotary instrument combined with ultrasonic irrigation of a 2.5% NaOCl solution (Group A)
Number of subjects: 300
Study 26406018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo Ni‐Ti rotary instrument combined with ultrasonic irrigation of an active silver ion antibacterial solution (Group B)
Number of subjects: 300
Study 26406018 — intervention group
Group type: COMPARATOR
Intervention: Syringe irrigation of a 2.5% NaOCl solution (Group C)
Number of subjects: 300
Study 23714651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit-4-Fun program (8-week multi-component intervention)
Number of subjects: 213
Study 23714651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit-4-Fun program
Number of subjects: 213
Study 20694469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) treatment, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine, administered once in September, October, and November (3 doses total)
Number of subjects: 60
Study 20694469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19477300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 441
Study 19477300 — intervention group
Group type: COMPARATOR
Intervention: Low calorie healthy eating approach
Number of subjects: 441
Study 18046092 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (statin)
Number of subjects: 0
Study 18046092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering with statins
Number of subjects: 0
Study 18046092 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15612152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus fluorouracil plus leucovorin (FL)
Number of subjects: 2
Study 15612152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus irinotecan plus fluorouracil (IFL)
Number of subjects: 2
Study 15612152 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus IFL
Number of subjects: 2
Study 11575684 — intervention group
Group type: EXPERIMENTAL
Intervention: All Stars program administered by teachers
Number of subjects: 1655
Study 11575684 — intervention group
Group type: EXPERIMENTAL
Intervention: All Stars program administered by specialists
Number of subjects: 1655
Study 11575684 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1655
Study 9515799 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU plus levamisole
Number of subjects: 229
Study 9515799 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 229
Study 9515799 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 229
Study 9515799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-ras mutation
Number of subjects: 229
Study 9515799 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 overexpression
Number of subjects: 229
Study 9515799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneuploidy
Number of subjects: 229
Study 7997085 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2A treatment
Number of subjects: 35
Study 3421197 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐[3,3,3‐2H3]alanine
Number of subjects: 20
Study 3421197 — intervention group
Group type: COMPARATOR
Intervention: L‐[15N]‐alanine
Number of subjects: 20
Study 3421197 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet in obese subjects
Number of subjects: 20
Study 3421197 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state in healthy adults
Number of subjects: 20
Study 29450792 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant procedure with pictorial stimuli in a two-alternative discrimination task
Number of subjects: 2
Study 29450792 — intervention group
Group type: COMPARATOR
Intervention: Comparison to pigeons
Number of subjects: 2
Study 28452822 — intervention group
Group type: EXPERIMENTAL
Intervention: Valveless Trocar (VT)
Number of subjects: 56
Study 28452822 — intervention group
Group type: COMPARATOR
Intervention: Standard Trocar (ST)
Number of subjects: 56
Study 26134266 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated physician discussion groups (19 biweekly sessions for 9 months) with mindfulness and reflection elements
Number of subjects: 74
Study 26134266 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study 26134266 — intervention group
Group type: COMPARATOR
Intervention: Nontrial cohort (not specified)
Number of subjects: 74
Study 23116088 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff training plus a screening and referral protocol
Number of subjects: 216
Study 23116088 — intervention group
Group type: COMPARATOR
Intervention: Staff training
Number of subjects: 216
Study 23116088 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 216
Study 22136096 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 65
Study 22136096 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 65
Study 22136096 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 65
Study 18365893 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (80-90% of VO(2peak))
Number of subjects: 17
Study 18365893 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity exercise (50-60% of VO(2peak))
Number of subjects: 17
Study 17057389 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador therapy (mistletoe preparation)
Number of subjects: 122
Study 17057389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mistletoe therapy)
Number of subjects: 122
Study 12776030 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 111
Study 12776030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 10653230 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colectomy (LAC)
Number of subjects: 255
Study 10653230 — intervention group
Group type: COMPARATOR
Intervention: Open segmental colectomy (OC)
Number of subjects: 255
Study 9100997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 50 mg bromfenac
Number of subjects: 12
Study 9100997 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 50 mg bromfenac
Number of subjects: 12
Study 8263444 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections given inside the mental foramen
Number of subjects: 30
Study 8263444 — intervention group
Group type: COMPARATOR
Intervention: Injections given outside the mental foramen
Number of subjects: 30
Study 8263444 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections given inside or outside the mental foramen
Number of subjects: 30
Study 7235209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 31688620 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea ordered by residents after policy change
Number of subjects: 209
Study 31688620 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea ordered by residents before policy change
Number of subjects: 209
Study 30334340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 64
Study 28758802 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 897
Study 28758802 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 897
Study 28758802 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg
Number of subjects: 897
Study 26088759 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based early goal-directed therapy (EGDT)
Number of subjects: 1351
Study 26088759 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based standard therapy
Number of subjects: 1351
Study 26088759 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1351
Study 26088759 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based therapy (EGDT and standard therapy combined)
Number of subjects: 1351
Study 26088759 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based EGDT
Number of subjects: 1351
Study 26088759 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1351
Study 24145346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m²) plus carboplatin (AUC 6) plus bevacizumab (15 mg/kg) followed by maintenance pemetrexed plus bevacizumab (PemCBev)
Number of subjects: 939
Study 24145346 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (200 mg/m²) plus carboplatin (AUC 6) plus bevacizumab (15 mg/kg) followed by maintenance bevacizumab (PacCBev)
Number of subjects: 939
Study 24145346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus bevacizumab (PemCBev)
Number of subjects: 939
Study 24145346 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin plus bevacizumab (PacCBev)
Number of subjects: 939
Study 21326612 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliably predictable rewards
Number of subjects: 0
Study 21326612 — intervention group
Group type: COMPARATOR
Intervention: Less predictable rewards
Number of subjects: 0
Study 19647206 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised homeopathic medicines (6C potency, oral liquid, two doses at baseline and 12 hours later)
Number of subjects: 100
Study 19647206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17223865 — intervention group
Group type: EXPERIMENTAL
Intervention: Rambazole, 1 mg, once daily for 8 weeks
Number of subjects: 6
Study 17151582 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate
Number of subjects: 20
Study 17151582 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 20
Study 12719848 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery performed at night (after 9 p.m.)
Number of subjects: 170
Study 12719848 — intervention group
Group type: COMPARATOR
Intervention: Surgery performed during the day
Number of subjects: 170
Study 10357731 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter meal (100 g)
Number of subjects: 10
Study 10357731 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil meal (80 g)
Number of subjects: 10
Study 10357731 — intervention group
Group type: COMPARATOR
Intervention: Control meal (energy-free soup with 50 g carbohydrate)
Number of subjects: 10
Study 7675971 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI-RIMA combination treatment (fluvoxamine and moclobemide)
Number of subjects: 18
Study 7675971 — intervention group
Group type: COMPARATOR
Intervention: SSRI monotherapy (fluvoxamine only)
Number of subjects: 18
Study 1971539 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 18
Study 1971539 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 18
Study 1971539 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 18
Study 1971539 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 18
Study 7082023 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared radiation
Number of subjects: 0
Study 7082023 — intervention group
Group type: COMPARATOR
Intervention: Heat administered before or after UV exposure
Number of subjects: 0
Study 31218938 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative MRI measurements of multifidus muscle signal intensity
Number of subjects: 90
Study 31218938 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative MRI grading of multifidus muscle fat content
Number of subjects: 90
Study 31218938 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between fat content and severity of nerve compression
Number of subjects: 90
Study 28477497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 0
Study 28477497 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI) anhedonia subscale
Number of subjects: 0
Study 26359750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) plus Specialist Medical Care (SMC)
Number of subjects: 641
Study 26359750 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET) plus Specialist Medical Care (SMC)
Number of subjects: 641
Study 26359750 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT) plus Specialist Medical Care (SMC)
Number of subjects: 641
Study 26359750 — intervention group
Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC) alone
Number of subjects: 641
Study 26359750 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET) vs Adaptive Pacing Therapy (APT)
Number of subjects: 641
Study 23881677 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD diet with chelated trace minerals, organic selenium yeast, direct-fed microbials, and Yucca schidigera extract
Number of subjects: 10
Study 23881677 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD diet with organic selenium yeast
Number of subjects: 10
Study 23881677 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD diet
Number of subjects: 10
Study 23881677 — intervention group
Group type: COMPARATOR
Intervention: CTRL diet
Number of subjects: 10
Study 23881677 — intervention group
Group type: EXPERIMENTAL
Intervention: Feces stockpiled to simulate a crude composting method
Number of subjects: 10
Study 23881677 — intervention group
Group type: EXPERIMENTAL
Intervention: Feces stockpile temperature
Number of subjects: 10
Study 22108275 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tolerable dose of valsartan (up to 320 mg/day)
Number of subjects: 1116
Study 22108275 — intervention group
Group type: COMPARATOR
Intervention: Usual dose of valsartan (80 mg/day)
Number of subjects: 1116
Study 18516718 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg single dose)
Number of subjects: 20
Study 18516718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16581685 — intervention group
Group type: EXPERIMENTAL
Intervention: Red LED therapy (20 min, 96 J/cm2, 633 nm)
Number of subjects: 10
Study 16581685 — intervention group
Group type: COMPARATOR
Intervention: Unirradiated control
Number of subjects: 10
Study 14529770 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with cisplatin (20 mg/m(2)) and twice-daily accelerated irradiation (1.8 Gy to pelvis, 1.6 Gy to tumor)
Number of subjects: 52
Study 14529770 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with MCV (methotrexate, cisplatin, vinblastine)
Number of subjects: 52
Study 14529770 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction and consolidation chemotherapy
Number of subjects: 52
Study 14529770 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy
Number of subjects: 52
Study 14529770 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction and consolidation RT
Number of subjects: 52
Study 14529770 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival, bladder-intact survival, locoregional failure, distant metastasis
Number of subjects: 52
Study 10980253 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contract theory
Number of subjects: 0
Study 10980253 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard management theory
Number of subjects: 0
Study 10980253 — intervention group
Group type: COMPARATOR
Intervention: Relevance theory
Number of subjects: 0
Study 8629680 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine treatment (clonazepam, alprazolam, or other benzodiazepines)
Number of subjects: 170
Study 8629680 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam nightly
Number of subjects: 170
Study 8629680 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic alprazolam treatment and other benzodiazepine treatments
Number of subjects: 170
Study 1457360 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 200
Study 1457360 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CAFt: cyclophosphamide 500 mg m‐2 + doxorubicin 40 mg/m‐2 + ftorafur 20 mg kg‐1 orally day 1‐14)
Number of subjects: 200
Study 1457360 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy and adjuvant chemotherapy
Number of subjects: 200
Study 1457360 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation, adjuvant chemotherapy and tamoxifen (40 mg daily for 2 years)
Number of subjects: 200
Study 6373547 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (twice daily at doses that reduced resting heart rate by 25%)
Number of subjects: 74
Study 6373547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 74
Study 30160086 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume plyometric training group (LPG=10 participants)
Number of subjects: 21
Study 30160086 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume plyometric training group (HPG=11 participants)
Number of subjects: 21
Study 29415330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10^9 colony-forming units) taken daily by mothers from 14-16 weeks of gestation until 6 months post-partum if breastfeeding
Number of subjects: 423
Study 29415330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 29415330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (mother and child intervention)
Number of subjects: 423
Study 26966087 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight cannula group (n=20)
Number of subjects: 40
Study 26966087 — intervention group
Group type: COMPARATOR
Intervention: Angled cannula group (n=20)
Number of subjects: 40
Study 26966087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24678937 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with self-expanding transcatheter valve
Number of subjects: 795
Study 24678937 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 795
Study 22935444 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 2388
Study 22935444 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 2388
Study 19735984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling women (late luteal phase)
Number of subjects: 84